- Company
- New TED drug 'Tepezza' under review for marketing approval
- by Eo, Yun-Ho Feb 10, 2025 05:50am
- The commercialization of 'Tepezza,' a targeted treatment for Thyroid Eye Disease, is expected. According to industry sources, the Ministry of Food and Drug Safety (MFDS) is reviewing the approval of the Thyroid Eye Disease (TED) treatment, Tepezza (teprotumumab). This drug was designated as an orphan drug in South Korea in August 2024.
- Company
- Will Keytruda’s reimbursement standards be set this time?
- by Whang, byung-woo Feb 7, 2025 05:52am
- Keytruda, for which MSD had submitted reimbursement applications to extend its coverage to 17 indications, is gaining industry attention as it is expected to be presented to the Cancer Disease Deliberation Committee for the first time this year. According to industry sources, MSD Korea's Keytruda (pembrolizumab) will be presented to the K
- Company
- Will the non-reimb status of 'Padcev' change this year?
- by Eo, Yun-Ho Feb 7, 2025 05:51am
- The industry is paying attention to the progress of reimbursing monotherapy·combination therapy of 'Padcev,' the new ADC drug for bladder cancer. Astellas Korea's Antibody-Drug Conjugates (ADC) Padcev (enfortumab) is expected to be considered for the Cancer Disease Review Committee of the Health Insurance Review and Assessment Service (HI
- Company
- CKD to distribute·sell Bayer's 'Nexavar'·'Stivarga' in KOR
- by Kim, Jin-Gu Feb 7, 2025 05:51am
- Chong Kun Dang Pharm announced on February 6 that it has signed an exclusive sales agreement with Bayer Korea for the advanced hepatocellular carcinoma treatments 'Nexavar (sorafenib)'·'Stivarga (regorafenib).' Based on this contract, Chong Kun Dang Pharm will be responsible for exclusive distribution·sales·marketing of Nexavar and Sti
- Company
- ‘Leqvio reduces LDL-C with twice-yearly dose’
- by Son, Hyung Min Feb 7, 2025 05:51am
- While the “the lower, the better” mantra in LDL-cholesterol (LDL-C) treatment is gaining traction around the world, achieving and maintaining target levels is challenging due to the patients’ poor adherence to existing therapies. In the United States, 50% of patients who are prescribed statins stop taking them within one year, and only 5% rem
- Company
- China rises as global R&D leader, K-bio not in top 50
- by Cha, Jihyun Feb 6, 2025 05:57am
- The R&D investment gap between Korean biopharmaceutical companies and Big Pharma is increasing. Analysis suggests that Korean companies must seek measures to respond to competition for next-generation technology as the R&D investment centers around the United States and China. On February 5, the Korea Chamber of Commerce and Industry (KCCI) a
- Company
- Baxter’s Renal Care Unit spinoff Vantive is launched
- by Whang, byung-woo Feb 6, 2025 05:56am
- With the acquisition process complete for Baxter's Renal Care business, it has newly launched as Vantive, a new company specializing in kidney and life-sustaining organ therapies. The spin-off follows the acquisition of Baxter's Kidney Care business by funds managed by global investment firm The Carlyle Group. As an independent company
- Company
- Imminent launch of the 3rd new CAR-T-cell therapy 'Yescarta'
- by Eo, Yun-Ho Feb 6, 2025 05:56am
- The third CAR-T-cell therapy 'Yescarta' is expected to be commercialized in South Korea. According to industry sources, Gilead Sciences submitted documentation for the approval of the CAR-T-cell therapy, Yescarta (axicabtagene ciloleucel), and the Ministry of Food and Drug Safety (MFDS) is currently conducting the review. Yescarta was
- Company
- 1st to exceed KRW 1T sales…Pfizer's ESG initiatives
- by Whang, byung-woo Feb 5, 2025 05:52am
- Pfizer Korea, the first to exceed KRW 1 trillion in sales from COVID-19 vaccine·treatments, continues strengthening its sustainable business management based on the ESG initiative. After recording KRW 3 trillion in 2022 during the COVID-19 pandemic, Pifzer Korea's sales robustly decreased. However, despite unusual circumstances, the i
- Company
- Multiple sclerosis drug Ocrevus may soon be reimbursed
- by Eo, Yun-Ho Feb 5, 2025 05:52am
- The new multiple sclerosis drug Ocrevus is expected to be listed for reimbursement in Kore. According to industry sources, Roche Korea has completed negotiations with the National Health Insurance Service on the drug price of Ocrevus (ocrelizumab) for relapsing multiple sclerosis (MS). As a result, the drug is expected to be reimbursed
